These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 25654990)

  • 21. Clinical utility of circulating tumor DNA for colorectal cancer.
    Osumi H; Shinozaki E; Yamaguchi K; Zembutsu H
    Cancer Sci; 2019 Apr; 110(4):1148-1155. PubMed ID: 30742729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating tumour DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection.
    Symonds EL; Pedersen SK; Murray DH; Jedi M; Byrne SE; Rabbitt P; Baker RT; Bastin D; Young GP
    Clin Epigenetics; 2018; 10():63. PubMed ID: 29796114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence.
    Gassa A; Fassunke J; Schueten S; Kuhlmann L; Scherer M; Qien J; Zhao Y; Michel M; Loeser H; Wolf J; Buettner R; Doerr F; Heldwein M; Hagmeyer L; Frank K; Merkelbach-Bruse S; Quaas A; Bruns C; Hekmat K; Weiss J; Wahlers T; Alakus H
    Lung Cancer; 2021 Jan; 151():91-96. PubMed ID: 33257044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker.
    Garrigou S; Perkins G; Garlan F; Normand C; Didelot A; Le Corre D; Peyvandi S; Mulot C; Niarra R; Aucouturier P; Chatellier G; Nizard P; Perez-Toralla K; Zonta E; Charpy C; Pujals A; Barau C; Bouché O; Emile JF; Pezet D; Bibeau F; Hutchison JB; Link DR; Zaanan A; Laurent-Puig P; Sobhani I; Taly V
    Clin Chem; 2016 Aug; 62(8):1129-39. PubMed ID: 27251038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
    Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
    Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma.
    Thomsen CB; Hansen TF; Andersen RF; Lindebjerg J; Jensen LH; Jakobsen A
    J Exp Clin Cancer Res; 2018 Mar; 37(1):55. PubMed ID: 29530101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer.
    Sefrioui D; Sarafan-Vasseur N; Beaussire L; Baretti M; Gangloff A; Blanchard F; Clatot F; Sabourin JC; Sesboüé R; Frebourg T; Michel P; Di Fiore F
    Dig Liver Dis; 2015 Oct; 47(10):884-90. PubMed ID: 26160500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.
    Barault L; Amatu A; Siravegna G; Ponzetti A; Moran S; Cassingena A; Mussolin B; Falcomatà C; Binder AM; Cristiano C; Oddo D; Guarrera S; Cancelliere C; Bustreo S; Bencardino K; Maden S; Vanzati A; Zavattari P; Matullo G; Truini M; Grady WM; Racca P; Michels KB; Siena S; Esteller M; Bardelli A; Sartore-Bianchi A; Di Nicolantonio F
    Gut; 2018 Nov; 67(11):1995-2005. PubMed ID: 28982739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Digital PCR of Genomic Rearrangements for Monitoring Circulating Tumour DNA.
    Do H; Cameron D; Molania R; Thapa B; Rivalland G; Mitchell PL; Murone C; John T; Papenfuss A; Dobrovic A
    Adv Exp Med Biol; 2016; 924():139-146. PubMed ID: 27753035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High fragmentation characterizes tumour-derived circulating DNA.
    Mouliere F; Robert B; Arnau Peyrotte E; Del Rio M; Ychou M; Molina F; Gongora C; Thierry AR
    PLoS One; 2011; 6(9):e23418. PubMed ID: 21909401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts.
    Thierry AR; Mouliere F; Gongora C; Ollier J; Robert B; Ychou M; Del Rio M; Molina F
    Nucleic Acids Res; 2010 Oct; 38(18):6159-75. PubMed ID: 20494973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.
    Garcia-Murillas I; Chopra N; Comino-Méndez I; Beaney M; Tovey H; Cutts RJ; Swift C; Kriplani D; Afentakis M; Hrebien S; Walsh-Crestani G; Barry P; Johnston SRD; Ring A; Bliss J; Russell S; Evans A; Skene A; Wheatley D; Dowsett M; Smith IE; Turner NC
    JAMA Oncol; 2019 Oct; 5(10):1473-1478. PubMed ID: 31369045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.
    van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM
    BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer.
    Kasi PM; Sawyer S; Guilford J; Munro M; Ellers S; Wulff J; Hook N; Krinshpun S; Koyen Malashevich A; Malhotra M; Rodriguez A; Moshkevich S; Grothey A; Kopetz S; Billings P; Aleshin A
    BMJ Open; 2021 Sep; 11(9):e047831. PubMed ID: 34561256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
    Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
    BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
    Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
    Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective.
    Postel M; Roosen A; Laurent-Puig P; Taly V; Wang-Renault SF
    Expert Rev Mol Diagn; 2018 Jan; 18(1):7-17. PubMed ID: 29115895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients.
    Olmedillas López S; García-Olmo DC; García-Arranz M; Guadalajara H; Pastor C; García-Olmo D
    Int J Mol Sci; 2016 Apr; 17(4):484. PubMed ID: 27043547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer.
    Symonds EL; Pedersen SK; Murray D; Byrne SE; Roy A; Karapetis C; Hollington P; Rabbitt P; Jones FS; LaPointe L; Segelov E; Young GP
    Cancer; 2020 Apr; 126(7):1460-1469. PubMed ID: 31909823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.